For each country, the type of COVID-19 vaccine produced, the names of manufacturing facilities, steps of vaccine production and vaccine manufacturing platform are included.

By the end of January 2022, almost five billion COVID-19 vaccine doses were manufactured in China, making the country by far the largest producer of COVID-19 vaccines globally. While most vaccines were for domestic use, a considerable portion of vaccines was exported via sales and donations, mainly to lower or middle-income countries. In comparison to western mRNA vaccines such as Comirnaty or Spikevax, inactivated COVID-19 vaccines developed by Sinovac and Sinopharm have a lower efficacy rate.

As at January 2021, Bangladesh had received *********** doses of the AstraZeneca vaccine produced by the Serum Institute of India. India is one of the biggest producers of the vaccine worldwide. On January 20, the government of India launched its "Vaccine Maitri" (Vaccine Friendship) initiative to support its neighboring countries as well as countries with a significant number of Indian citizens.

The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035, registering a compound annual growth rate (CAGR) of 7.4% over the forecast period

Country-Wise Outlook

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t

Vaccine Contract Manufacturing Market Outlook

According to our latest research, the global vaccine contract manufacturing market size reached USD 4.8 billion in 2024, reflecting robust demand and expansion across key regions. The market is projected to grow at a CAGR of 9.2% from 2025 to 2033, reaching an estimated USD 10.7 billion by 2033. This dynamic growth is primarily driven by the increasing outsourcing activities among vaccine developers, a surge in demand for advanced vaccine platforms, and the rising prevalence of infectious diseases globally. As per our analysis, the market is witnessing a paradigm shift as pharmaceutical and biotechnology companies increasingly rely on specialized contract manufacturing organizations (CMOs) to streamline production, reduce costs, and accelerate time-to-market for critical vaccines.

A key growth factor for the vaccine contract manufacturing market is the ongoing innovation in vaccine technologies, particularly with the emergence of mRNA and viral vector platforms. The COVID-19 pandemic has significantly accelerated the adoption of these advanced vaccine technologies, prompting both established and emerging vaccine developers to seek the expertise and infrastructure of CMOs. Contract manufacturers offer scalable production capabilities, specialized knowledge in regulatory compliance, and the flexibility to adapt to rapidly evolving vaccine formulations. The ability of CMOs to provide end-to-end services, from bulk manufacturing to fill-finish and packaging, is proving critical for companies aiming to keep pace with global vaccination campaigns and respond to emerging infectious threats.

Another driving force behind the expansion of the vaccine contract manufacturing market is the increasing complexity of vaccine development and the stringent regulatory landscape. The need for high-quality, GMP-compliant manufacturing processes has led many pharmaceutical and biotechnology companies to partner with CMOs that possess state-of-the-art facilities and deep regulatory expertise. These partnerships help vaccine developers mitigate risks, ensure product quality, and expedite regulatory approvals. Furthermore, the rising demand for pediatric, adult, and travel vaccines, coupled with the ongoing efforts to eradicate diseases such as polio, measles, and hepatitis, is fueling the need for efficient and reliable contract manufacturing solutions worldwide.

The market's growth trajectory is also shaped by the globalization of vaccine supply chains and the increasing emphasis on cost optimization. Pharmaceutical companies are increasingly outsourcing non-core activities to CMOs to focus on research and innovation while leveraging the operational efficiencies and economies of scale offered by contract manufacturers. This trend is particularly prominent among small and medium-sized enterprises (SMEs) and emerging biotechnology companies that lack the capital-intensive infrastructure required for large-scale vaccine production. As governments and international health organizations intensify efforts to enhance global immunization coverage, the demand for flexible, high-volume vaccine manufacturing solutions is expected to remain strong throughout the forecast period.

From a regional perspective, North America currently dominates the vaccine contract manufacturing market, accounting for the largest revenue share in 2024, followed by Europe and the Asia Pacific. The presence of leading pharmaceutical companies, robust healthcare infrastructure, and a favorable regulatory environment are key contributors to North America's leadership. However, the Asia Pacific region is anticipated to witness the fastest growth rate during the forecast period, driven by significant investments in biomanufacturing capacity, expanding vaccine R&D activities, and increasing government support for immunization programs. Latin America and the Middle East & Africa are also emerging as attractive markets, supported by rising healthcare expenditures and growing awareness of vaccine-preventable diseases.

Servi

COVID-19 Vaccines-Production Capacity & Development Timeline Market Outlook

According to our latest research, the global COVID-19 vaccines market size reached USD 40.2 billion in 2024, reflecting a significant contraction from the pandemic’s peak but remaining a critical segment of the global biopharmaceutical industry. The market is projected to grow at a CAGR of 3.7% from 2025 to 2033, reaching a forecasted value of USD 56.7 billion by 2033. This growth is primarily driven by the ongoing need for booster vaccinations, the emergence of new viral variants, and sustained investments in vaccine research and production capabilities worldwide. The market’s resilience is further supported by government procurement programs and the expansion of vaccine access in emerging economies.

The evolution of the COVID-19 vaccines market is shaped by several growth factors, notably the persistent circulation of SARS-CoV-2 and the continuous emergence of new variants that challenge existing immunity levels. Governments and health organizations worldwide remain vigilant, prioritizing the development and distribution of updated vaccines to counter variant-driven outbreaks. The introduction of bivalent and multivalent vaccines, designed to offer protection against multiple strains, has spurred ongoing demand. Furthermore, the increasing reliance on annual or biannual booster doses for vulnerable populations, such as the elderly and immunocompromised individuals, ensures a steady baseline for vaccine consumption. The integration of COVID-19 vaccination into routine immunization schedules is also anticipated to contribute to market stability over the forecast period.

Another key driver is the remarkable progress in vaccine technology, particularly the rapid advancement and deployment of mRNA vaccine platforms. The success of mRNA vaccines has not only revolutionized the response to COVID-19 but has also accelerated research and development for other infectious diseases. This technological leap has encouraged investments in flexible manufacturing infrastructure, enabling faster adaptation to emerging threats and enhancing global production capacity. Additionally, partnerships between pharmaceutical companies, governments, and contract manufacturing organizations (CMOs) have optimized supply chains, improved scalability, and facilitated technology transfer to developing regions. These collaborative efforts are essential for maintaining readiness against future pandemics and for addressing ongoing global health challenges.

Market growth is further bolstered by proactive government policies and international collaborations aimed at ensuring equitable vaccine distribution. Initiatives such as COVAX and bilateral agreements have played a crucial role in expanding vaccine access to low- and middle-income countries, thereby stimulating demand and supporting market expansion. The increasing participation of private procurement channels, including hospitals, clinics, and pharmacies, has diversified distribution networks and improved accessibility for broader populations. Moreover, the push for localized manufacturing and regulatory harmonization is streamlining vaccine approval processes and reducing dependency on a limited number of global suppliers. These trends collectively underpin the sustained growth trajectory of the COVID-19 vaccines market.

Regionally, North America and Europe continue to dominate the COVID-19 vaccines market, accounting for the largest shares due to robust healthcare infrastructure, high vaccination rates, and substantial government funding. However, the Asia Pacific region is exhibiting the fastest growth, driven by large-scale immunization campaigns, expanding manufacturing capabilities, and rising awareness about the importance of vaccination. Countries such as China and India are emerging as significant players in both vaccine production and consumption, supported by favorable policy frameworks and increasing investments in biotechnology. Latin America and the Middle East & Africa are also witnessing gradual improvements in vaccine coverage, although challenges related to infrastructure and affordability persist. Overall, the regional dynamics are expected to evolve as global efforts intensify to achieve comprehensive vaccine coverage and pandemic preparedness.

As of March 9, 2021, India has secured some 2.2 billion COVID-19 vaccine doses through contracts in total. India chose to purchase vaccines manufactured by AstraZeneca (Oxford), Novavax, and the Russian Gamaleya Institute. However, the overwhelming majority of these doses have yet to be produced and delivered. This statistic shows the size of COVID-19 vaccine contracts based on number of doses secured by countries through contracts with manufacturers. The AstraZeneca/Oxford vaccine is by far the most sought COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines need ultra cold storage.

By the end of January, the Beijing Institute of Biological Products Co. Ltd. (BIBP), a subsidiary of Chinese pharmaceutical giant Sinopharm, had produced almost 2.3 billion COVID-19 vaccine doses, ranking it the second-largest manufacturer of COVID-19 vaccines in the country. Although most Sinopharm BIBP vaccines are used domestically within China, a large number of doses were also exported worldwide through sales and donations. The company also constructed production sites with local partners in a number of countries to enable vaccine productions locally.

Covid-19 Vaccine Market size was valued at USD 7.64 Billion in 2024 and is projected to reach USD 12.64 Billion by 2032, growing at a CAGR of 7.16% during the forecasted period 2026 to 2032.

The COVID-19 vaccine market is driven by the persistent threat of emerging variants, which necessitates ongoing vaccine development and booster campaigns to ensure population immunity. Government funding and international collaborations, such as those facilitated by COVAX, play a pivotal role in accelerating research, production, and equitable distribution. Advances in mRNA and other vaccine technologies have further spurred innovation in the sector. Additionally, increasing public awareness of vaccination benefits and the integration of vaccines into routine immunization programs contribute to sustained demand. The expansion of cold-chain logistics and regional vaccine manufacturing capabilities has also enhanced market accessibility, particularly in low- and middle-income countries.

COVID-19 RNA Vaccine Market Outlook

The global COVID-19 RNA Vaccine market size was valued at approximately USD 25 billion in 2023, and it is projected to reach USD 80 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 14% during the forecast period. The significant growth factor driving this market is the unprecedented urgency and global demand for effective immunization solutions to combat the COVID-19 pandemic. The rapid development, approval, and distribution of RNA vaccines such as mRNA-1273 and BNT162b2 have revolutionized the vaccine industry, providing a novel mechanism that utilizes messenger RNA to instruct cells to produce viral proteins, thereby triggering an immune response.

The primary growth factor for the COVID-19 RNA vaccine market is the efficacy and speed of RNA vaccine development. Traditional vaccine development can take years, whereas RNA vaccines can be developed and scaled up quickly due to their synthetic nature and the simplicity of their manufacturing processes. This rapid development capability has been crucial in addressing the urgent need for COVID-19 vaccines. Additionally, RNA vaccines have exhibited high efficacy rates in clinical trials, further bolstering public confidence and demand. Innovations in RNA technology are also paving the way for improvements in storage and distribution, making these vaccines more accessible globally.

Another significant growth driver is the ongoing threat of new COVID-19 variants. As the virus mutates, the need for adaptable and quickly producible vaccines becomes more pressing. RNA vaccines offer a flexible platform that can be rapidly modified to target new viral strains. This adaptability ensures continued relevance and demand for RNA vaccines in the long term, as booster shots and updated vaccines become necessary to maintain immunity against evolving virus strains. Furthermore, global vaccination campaigns and government initiatives to secure vaccine supplies are playing a pivotal role in market growth.

The scalability of RNA vaccine production is a key factor contributing to market growth. Unlike traditional vaccines that require cell cultures or animal products, RNA vaccines can be synthesized in large quantities using relatively simple and scalable biochemical processes. This ease of production not only accelerates the manufacturing timeline but also allows for cost-effective mass production. The increased production capacity has enabled manufacturers to meet the global demand more efficiently, ensuring widespread distribution and administration of vaccines.

The emergence of mRNA Vaccines & Therapeutics has been a pivotal development in the fight against COVID-19. These vaccines, which utilize messenger RNA to instruct cells to produce viral proteins, have not only proven effective against the original strain of the virus but also offer a flexible platform for rapid adaptation to new variants. This adaptability is crucial as the virus continues to evolve, presenting new challenges in maintaining public health. The success of mRNA vaccines has sparked a broader interest in their potential applications beyond infectious diseases, exploring possibilities in cancer treatment and other therapeutic areas. This innovation marks a significant shift in vaccine technology, promising a new era of medical advancements.

The regional outlook for the COVID-19 RNA vaccine market indicates robust growth across various geographies. North America, particularly the United States, has been a leading region in terms of vaccine development and distribution, supported by substantial government funding and advanced healthcare infrastructure. Europe follows closely, with significant contributions from countries like Germany and the UK. The Asia Pacific region is also witnessing remarkable growth, driven by initiatives in countries such as China and India to ramp up vaccine production and distribution. Latin America and the Middle East & Africa are gradually increasing their market shares through international collaborations and local manufacturing efforts.

Vaccine Type Analysis

The COVID-19 RNA vaccine market is segmented by vaccine type, with major categories including mRNA-1273, BNT162b2, CVnCoV, ARCoV, and others. mRNA-1273, developed by Moderna, has been a frontrunner in the race to vaccinate the global population. Its high efficacy rate, coupled with robust production capabilities, has made it a significant player in the market. Unlike traditional vaccines, mRNA-12

Immunization of pregnant women against seasonal influenza remains limited in low- and lower-middle-income countries despite being recommended by the World Health Organization (WHO). The WHO/PATH Maternal Influenza Immunization Project was created to identify and address obstacles to delivering influenza vaccines to pregnant women in low resource setting. To gain a better understanding of potential demand from this target group, we developed a model simulating pregnant women populations eligible for vaccination during antenatal care (ANC) services in all low- and lower-middle-income countries. We assessed potential vaccine demand in the context of both seasonal and year-round vaccination strategies and identified the ways that immunization programs may be affected by availability gaps in supply linked to current vaccine production cycles and shelf life duration. Results of our analysis, which includes 54 eligible countries in 2015 for New Vaccine Support from Gavi, the Vaccine Alliance, suggest the demand for influenza vaccines could be 7.7 to 16.0 million doses in 2020, and 27.0 to 61.7 million doses by 2029. If current trends in production capacity and actual production of seasonal influenza vaccines were to continue, global vaccine supply would be sufficient to meet this additional demand—although a majority of countries would face implementation issues linked to timing of supply.

European Sold Production of Vaccines for Veterinary Medicine by Country, 2023 Discover more data with ReportLinker!

Coronavirus Vaccine Market Outlook

The global market size for coronavirus vaccines was valued at around USD 45 billion in 2023, and it is expected to grow at a compound annual growth rate (CAGR) of 6.5% to reach approximately USD 79.8 billion by 2032. The primary growth factors driving this market include the ongoing need to manage COVID-19 outbreaks, the emergence of new virus variants, and the increasing global emphasis on pandemic preparedness and public health infrastructure enhancement.

One of the critical growth factors for the coronavirus vaccine market is the rising understanding of the long-term necessity for vaccination programs. Unlike initial assumptions that the pandemic could be quickly eradicated, it has become evident that COVID-19 may become endemic, requiring consistent and possibly seasonal vaccination efforts. This understanding has led both governments and private institutions to invest heavily in vaccine development, stockpiling, and distribution networks. Moreover, the introduction of booster doses to combat waning immunity has further solidified the market's growth trajectory.

Technological advancements in vaccine development have also played a significant role in the market's expansion. The rapid development and deployment of mRNA vaccines, such as those produced by Pfizer-BioNTech and Moderna, have set new benchmarks in the pharmaceutical industry. These innovations have not only increased the efficacy of vaccines but also reduced the time required for development and approval. This accelerated timeline is crucial for responding to new variants and potential future pandemics, driving further investments in cutting-edge vaccine technologies.

Regulatory support and international collaborations have also significantly influenced market growth. Governments worldwide have been proactive in approving emergency use authorizations and providing funding for vaccine research and development. Additionally, initiatives such as COVAX, led by the World Health Organization (WHO) and other global health organizations, aim to ensure equitable access to vaccines, particularly in low- and middle-income countries. These collaborative efforts are crucial for maintaining global health security and are anticipated to boost market demand.

From a regional perspective, North America and Europe have shown robust investments in vaccination programs and public health infrastructure, contributing to substantial market shares. However, the Asia Pacific region is expected to witness the highest growth rate, driven by large population bases, increasing healthcare spending, and concerted efforts to enhance vaccination coverage. Latin America and the Middle East & Africa are also emerging markets, with growing awareness and governmental initiatives to improve vaccine access and distribution.

Vaccine Type Analysis

The coronavirus vaccine market is segmented by vaccine type into mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. Each of these types offers unique benefits and challenges, contributing to the overall diversity and resilience of the vaccine portfolio. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have revolutionized the market with their high efficacy rates, rapid development cycles, and adaptability to new variants. These vaccines are set to dominate the market due to their technological superiority and strong clinical outcomes.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. Vaccines like the AstraZeneca-Oxford and Johnson & Johnson's Janssen fall into this category. These vaccines have shown efficacy in preventing severe disease and are easier to store and transport compared to mRNA vaccines. Their relatively lower production costs make them a viable option for mass immunization programs, especially in developing countries.

Protein subunit vaccines, which use harmless pieces of the virus to stimulate an immune response, are also gaining traction. Novavax is a key player in this segment, with its vaccine demonstrating strong efficacy and safety profiles. These vaccines are particularly appealing for individuals who may have allergic reactions to mRNA vaccines, offering an alternative that still provides robust protection. The scalability and stability of protein subunit vaccines make them an important component of the global vaccination strategy.

Inactivated vaccines, which use killed versions of the virus, have been

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Due to widespread Covid vaccination rates, the global trade in vaccines reached $42.5B, the highest level ever. Belgium topped the country rankings by the value of exports this year, followed by Germany and the U.S. Growing global demand stimulates the rapid expansion of Covid vaccine production facilities in the EU.

European Sold Production of Antisera and Vaccines Share by Country (Euros), 2023 Discover more data with ReportLinker!

As of April 26, 2023, roughly 367 million Pfizer-BioNTech COVID-19 vaccine doses had been administered in the United States. This statistic shows the number of COVID-19 vaccinations administered in the United States as of April 26, 2023, by manufacturer.

According to Cognitive Market Research, the global Yellow Fever Vaccine market size will be USD 4528.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 5.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1811.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1358.55 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1041.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 226.43 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 90.57 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
The Sylvatic Yellow Fever category is the fastest-growing segment of the Yellow Fever Vaccine industry

Market Dynamics of Yellow Fever Vaccine Market

Key Drivers for Yellow Fever Vaccine Market

Rising Incidence of Yellow Fever to Boost Market Growth

Yellow fever is a potentially fatal viral disease spread by infected mosquitoes. According to the World Health Organization (WHO), as of 2023, 34 countries in Africa and 13 in Central and South America are either endemic or have endemic regions for yellow fever. Between August 26 and November 29, 2022, 22 additional confirmed cases were reported across ten countries. However, after a retrospective review, only seven new confirmed cases and one death were identified. Since 2021, in the WHO African Region, a total of 203 confirmed cases and 252 probable cases of yellow fever have been reported, with 40 deaths, resulting in a case fatality rate (CFR) of 9%. Among the confirmed cases, 23 deaths were recorded, reflecting a CFR of 11%. The high CFR among confirmed cases remained consistent, with 17 deaths (11%) in 2021 and six deaths (12%) in 2022. This increasing disease burden is driving significant demand for yellow fever vaccines, especially in endemic areas. Recent severe outbreaks in Brazil, Angola, and the Democratic Republic of Congo have intensified global awareness and the need for preventive measures, further stimulating the vaccine market.

Expansion of Vaccination Programs to Drive Market Growth

In 2017, the WHO, in collaboration with UNICEF and Gavi, the Vaccine Alliance, launched the EYE Strategy to protect at-risk populations in 40 countries across Africa and the Americas through mass vaccination campaigns and by ensuring a sustainable vaccine supply. Since the start of the current outbreak (2021 to December 7, 2022), a total of 4,385,320 people have been vaccinated in five countries—Cameroon, the Central African Republic, Chad, Ghana, and Kenya—through the ICG-supported response. A reactive campaign in Kembe Satema, Central African Republic, from November 2 to 19, 2022, achieved 101.7% coverage, while a campaign in Bambari, which ended on November 23, 2022, reached 87.7% coverage based on preliminary results. These efforts have accelerated vaccine deployment and expanded immunization programs, providing growth opportunities for vaccine manufacturers. Additionally, many countries in yellow fever-endemic regions have incorporated the vaccine into their national immunization schedules, ensuring steady demand. In several African and South American nations, yellow fever vaccination is mandatory for children, further boosting the market.

Restraint Factor for the Yellow Fever Vaccine Market

Vaccine Supply Shortages and High-Cost Will Limit Market Growth

Yellow fever vaccine production is concentrated among a limited number of manufacturers, leading to supply bottlenecks. This has caused periodic shortages, especially during large-scale outbreaks when demand surges. The production of the live-attenuated vaccine is complex, relying on chicken embryos for cultivation, which limits the ability to rapidly scale up production. In sudden outbreaks, vaccine demand often exceeds supply. The global stockpile maintained by the World Health Organization (WHO) is sometimes insufficient t...

Market Overview:

The global seasonal Influenza Vaccine market is expected to grow from USD 7.5 billion in 2017 to USD 11.8 billion by 2030, at a CAGR of 5.1% from 2022 to 2030. The growth in the market can be attributed to the increasing incidence of seasonal influenza, raising awareness about the benefits of vaccination, and technological advancements in vaccine production. Based on type, the global seasonal influenza vaccine sales market is segmented into trivalent influenza vaccine and quadrivalent influenza vaccine.

Product Definition:

A vaccine is a biological preparation that improves immunity to a particular disease. Seasonal Influenza Vaccine Sales usually refers to the sale of vaccines used to prevent seasonal influenza, also known as the flu. The importance of seasonal influenza vaccine sales is that they help protect people from getting sick during the flu season.

Trivalent Influenza Vaccine:

The trivalent influenza vaccine is a type of vaccine that provides protection against three strains of the flu; there are two types of vaccines available on the market, one trivalent and the other quadrivalent. Trivalent Influenza Vaccines have been available for many years whereas quadrivalent ones are relatively new. The difference between them is only in the number of viruses included in their composition, both provide a similar level of protection against the seasonal flu virus.

Quadrivalent Influenza Vaccine:

The quadrivalent influenza vaccine is a type of influenza vaccine that protects against four different strains of the flu. It is approved for use in people over 65 years of age and individuals with chronic conditions, such as cardiovascular disease, diabetes mellitus, renal disease, or immunosuppression. The seasonal flu vaccination has been recommended by the CDC since 2010 to reduce hospitalizations by 30% and deaths by 50%.

Application Insights:

Based on application, the global seasonal influenza vaccine market is segmented into children, adults, and the elderly. The adult segment held around 60% of the overall revenue share in 2015. This can be attributed to growing awareness about health hazards associated with circulating viruses and increasing healthcare spending in developed countries like the U.S., Germany, etc. The growing geriatric population across the globe is expected to boost demand for vaccines in upcoming years which would drive growth further during the forecast period. The elderly segment held another 40% of the overall revenue share in 2015 due to the growing incidence of diseases related to old age such as Alzheimer's disease, Parkinson disease, etc., especially in high-income countries like Japan and Italy respectively owing to which these two segments are expected generate significant demand for seasonal influenza vaccine over next eight years (through 2030).

Regional Analysis:

North America dominated the global market in terms of revenue share in 2020 with a value of USD X billion and is expected to grow at a lucrative rate over the forecast period. The presence of high-income countries such as the U.S., favorable government initiatives, and increasing awareness about seasonal vaccines are some factors attributing to its largest market share throughout the forecast period. Asia Pacific is anticipated to be one of the fastest growing regional markets from 2022 to 2030 owing to the rising demand for Flu Vaccine across this region due to the increasing number of susceptible people along with rapid economic development in emerging economies including China and India which are among top 10 countries where most people get infected each year (as per WHO). These two countries alone account for more than 50% population who get infected every year thus creating huge potential for seasonal influenza vaccine sales within the Asia Pacific region over the next eight years (as per GSK).

Growth Factors:

• Increasing awareness about the benefits of the seasonal influenza vaccine among people.
• Government initiatives and campaigns to promote vaccination against seasonal influenza.
• Growing demand for preventive healthcare services.
• Rising incidence of seasonal influenza outbreaks.
• Technological advancements in the manufacturing of seasonal influenza vaccines.

Report Scope